Alpha 2.0
Login Register
» Articles » PMID: 38779691

A Case of Severe Side Effects to Androgen Receptor Inhibitor and Consequently Switch to Radioligand Therapy in Early Castration Resistant Prostate Cancer

Overview
Journal Urol Case Rep
Specialty Urology
Date 2024 May 23
PMID 38779691
Authors
Andreas Tulipan
Clemens Kratochwil
Jacob Lilleby
Wolfgang Lilleby
Affiliations
Soon will be listed here.
Abstract

The development of potent novel androgen receptor inhibitors (ARi) such as apalutamide have improved the life expectancy in men with castration-resistant prostate cancer (CRPCa). However, some serious toxicity can occur limiting the choice of treatment in CRPCa. In our case, the patient experienced severe toxicity after initiation of apalutamide. Diagnostic PSMA-PET/CT confirmed the recurrence and tailored the treatment with Lu-PSMA-617 (RLT), a beta emitter radionuclide. RLT resulted in prolonged progression-free survival, thus postponing the commonly seen additional toxicity of chemotherapy. The case highlights the possibility of early RLT in PSMA avid tumors, a treatment with minimal side-effects.

Citing Articles

The role of PSMA-based radioligand therapy in hormone-sensitive prostate cancer.

Laudicella R, Bauckneht M, Burger I, Cacciola A, Fanti S, Farolfi A Eur J Nucl Med Mol Imaging. 2025; .

PMID: 39934300 DOI: 10.1007/s00259-025-07083-8.

References
1.
Sartor O, Morris M, Kraus B . Lutetium-177-PSMA-617 for Prostate Cancer. Reply. N Engl J Med. 2021; 385(26):2495-2496. DOI: 10.1056/NEJMc2116647. View
2.
Agarwal N, McQuarrie K, Bjartell A, Chowdhury S, Pereira de Santana Gomes A, Chung B . Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2019; 20(11):1518-1530. DOI: 10.1016/S1470-2045(19)30620-5. View
3.
Al-Batran S, Hozaeel W, Tauchert F, Hofheinz R, Hinke A, Windemuth-Kieselbach C . The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax). Ann Oncol. 2015; 26(6):1244-1248. DOI: 10.1093/annonc/mdv129. View
4.
Rathke H, Giesel F, Flechsig P, Kopka K, Mier W, Hohenfellner M . Repeated Lu-Labeled PSMA-617 Radioligand Therapy Using Treatment Activities of Up to 9.3 GBq. J Nucl Med. 2017; 59(3):459-465. DOI: 10.2967/jnumed.117.194209. View
5.
Freedland S, de Almeida Luz M, De Giorgi U, Gleave M, Gotto G, Pieczonka C . Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer. N Engl J Med. 2023; 389(16):1453-1465. DOI: 10.1056/NEJMoa2303974. View